Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative stem cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.
Up to 90% verified emails and mobile numbers, refreshed weekly.
Ernexa Therapeutics operates in the Biotechnology Research industry and is headquartered in United States.
Ernexa Therapeutics has approximately 11-50 employees employees.
Ernexa Therapeutics is based in Cambridge, Massachusetts, United States.
Yes. Ernexa Therapeutics is a publicly traded company.
You can reach Ernexa Therapeutics’s investor relations department through the contact section on their official website or directly via the investor relations email listed in their latest SEC filings.
Up to 90% verified emails and mobile numbers, backed by weekly job-change alerts.
An email pattern tells you the format. It does not tell you who works there now or whether an address still delivers. Scalelist returns verified contacts, checked at the point you build the list.